MOTS-c: the mouse and human studies
Reviewed 17 sourcesPublished by PepVault
MOTS-c improved insulin sensitivity and running in mice. Human studies have only measured the body's own levels. What each study found, and what's missing.

- Last reviewed
- Sources
- 17
- Questions
- 9
- Compounds
- 3
The short answer
MOTS-c is a 16-amino-acid peptide written in mitochondrial DNA. In mice, injections prevented diet-induced obesity and insulin resistance and improved running, even in old animals. In people, no published trial has given MOTS-c itself: studies measured the body's own levels, which rise with exercise and run lower in type 2 diabetes. The one human drug trial tested an analog, CB4211.
Evidence: Early: what MOTS-c does when given comes from mouse and cell studies; in people there are only measurements of the body's own MOTS-c and one unpublished phase 1 trial of an analog, CB4211.

What is MOTS-c?
Mitochondria, the structures inside cells that turn food and oxygen into usable energy, carry a small genome of their own. In a 2015 paper, a team at the University of Southern California described a short stretch of it, inside the gene for the mitochondria's 12S ribosomal RNA, that codes for a 16-amino-acid peptide. They named it MOTS-c, short for mitochondrial open reading frame of the 12S rRNA-c. Humanin, found earlier, is coded in mitochondrial DNA too1.
Its sequence is MRWQEMGYIFYPRKLR, one letter per amino acid2. Picture a string of 16 beads that the cell's power plants make and send out as a message. That is why MOTS-c is called a mitochondria-derived peptide.
Peptide SkySee MOTS-c as a molecule53 peptides as a night sky in 3D. Each star opens into its molecule, one bead per amino acid, with the measured shape where one exists.Open the Peptide Sky
How does MOTS-c work?
In the 2015 paper, the main target was skeletal muscle. Inside cells, MOTS-c slowed the folate cycle and the purine building it feeds, and that switched on AMPK, the cell's fuel gauge: an enzyme that turns on when energy runs low and tells the cell to take up and burn more glucose and fat1. The paper compared it with the diabetes drug metformin, which also switches on AMPK and also acts on the folate cycle1. Later papers call MOTS-c an exercise mimetic, a molecule that copies some effects of exercise7.
Later work found that MOTS-c also changes which genes in the cell's nucleus are read, including genes for metabolism and protein upkeep3, and in mouse muscle after a long downhill run it had moved into the nucleus in two of six samples4. That two-way traffic, a message from the mitochondrial genome steering the main one, is the most interesting idea in this research.
Everything in this section comes from cell and mouse studies (pepvault.app/glossary/in-vitro and pepvault.app/glossary/in-vivo). Results in mice often don't carry over to people.
What did the mouse studies find?
The animal results are what made MOTS-c famous. Given by injection, it kept mice from becoming insulin resistant, whether from aging or from a high-fat diet, and kept the diet from making them obese1. In a 2021 study it improved physical performance in young (2 months), middle-aged (12 months) and old (22 months) mice, and a course started at 23.5 months, three times a week, raised physical capacity and healthspan, the years lived in good health3. In young mice it helped on a rotating-rod test and on the treadmill, but not on grip strength3.

| Study | Animals | What was measured | Result |
|---|---|---|---|
| Lee 20151 | Mice | Insulin resistance and weight on a high-fat diet, and with age | Both prevented |
| Reynolds 20213 | Mice aged 2, 12 and 22 months | Running and physical performance | Improved at every age; late-life course raised healthspan |
| Hyatt 20224 | Untrained mice | One injection, then a running test | Running time up 12%, distance up 15% |
| Hyatt 20224 | Rats and mice given a running wheel for 4 to 8 weeks | MOTS-c in leg muscle | About 1.5 to 5 times higher than in sedentary mice |
| Kong 20255 | Islets from old mice; two diabetic mouse models | Senescence (cells that stop dividing) in insulin-making islets, and glucose tolerance | Both improved |
Every study page is at pepvault.app/research: start with pepvault.app/research/mots-c-lee-2015, pepvault.app/research/mots-c-reynolds-2021 and pepvault.app/research/mots-c-hyatt-2022.
The mouse doses were set per kilogram of body weight and injected into the belly cavity (Hyatt's single dose was 15 mg/kg4). Mouse and human bodies clear drugs at different rates, so these numbers don't convert to a human amount.
What have studies in people measured?
Every published human study of MOTS-c measured the MOTS-c the body already makes, in blood or in a small muscle sample. Some gave people exercise or heat and watched the level move; most compared groups at one point in time, which is an observational study (pepvault.app/glossary/observational-study). None of them gave anyone MOTS-c.
| Study | People | What changed |
|---|---|---|
| Reynolds 20213 | 10 sedentary young men, one cycling session | Muscle MOTS-c up 11.9-fold after exercise; blood up 1.6-fold during and 1.5-fold after, back to baseline 4 hours later |
| Dieli-Conwright 20217 | 49 breast cancer survivors, 16 weeks of exercise or usual care | Blood MOTS-c rose with exercise in non-Hispanic White women, not in Hispanic women |
| Elhusseiny 20258 | 19 active men, 2 weeks with one ankle immobilized | Repeated heat sessions raised blood MOTS-c; immobilization alone did not change it |
| D'Souza 20206 | Healthy men aged 18 to 81 | Blood MOTS-c lower with age; muscle MOTS-c about 1.5 times higher in men aged 45 to 55 and 70 to 81 than in men aged 18 to 30 |
| Ramanjaneya 20199 | 225 people with normal blood sugar, prediabetes or type 2 diabetes | Blood MOTS-c lower in type 2 diabetes; lower with higher HbA1c and glucose |
| Du 201810 | 97 children and teenagers | Lower in obese boys than in lean boys; no difference in girls |
| Qin 201811 | 40 patients tested for chest pain | Lower in those whose coronary blood flow responded poorly on an artery-lining (endothelial) test |

HbA1c is the three-month average of blood sugar (pepvault.app/glossary/hba1c). A 2024 meta-analysis (pepvault.app/glossary/meta-analysis) pooled 7 blood-level studies with 602 people: MOTS-c was lower in diabetes, but higher in obesity once overweight people were left out12. The obesity results point in opposite directions from study to study, so the levels are a research signal, not a test anyone uses in a clinic.
Do low MOTS-c levels mean you need more?
No study has shown that. A lower level next to a disease can be a cause, a result or a bystander, and an observational study can't tell those apart. What the data do show is that the body raises its own MOTS-c with exercise, in muscle most of all3, which is the one human finding people can act on without a vial.
The closest thing to cause and effect in people comes from genetics. Some people of Asian ancestry carry an Asian-specific mitochondrial DNA variant, m.1382A>C, that swaps one amino acid in MOTS-c, the lysine at position 14 for glutamine (K14Q). Across three cohorts with 27,527 people, men with the variant had more type 2 diabetes, and in one cohort only the least active men did13. In high-fat-fed male mice, normal MOTS-c lowered weight and improved glucose tolerance and the K14Q version did not13.

Has MOTS-c been tested as a drug in people?
Not in any published study. PubMed holds 267 records on MOTS-c (searched November 20, 2026), and none is a trial that gave it to people. The FDA's page on risky compounding substances (current as of April 22, 2026) says the agency "has not identified any human exposure data on drug products containing MOTs-C administered via any route," and that compounded versions may carry a risk of immunogenicity, an immune reaction against the peptide (pepvault.app/glossary/immunogenicity)14. Its legal status by country is at pepvault.app/peptides/mots-c/legal-status.
The one human drug trial tested an analog, a modified version designed to work better as a drug. CB4211, from CohBar, a company that two of the 2015 paper's authors consult for and hold shares in3, ran a randomized, placebo-controlled phase 1 trial with 88 people from 2018 to April 2021: healthy adults first, then 28 days of daily injections in people with fatty liver disease15. ClinicalTrials.gov lists it as completed with no results posted. The company's own annual report gave the topline numbers16:
| After 4 weeks | CB4211, 25 mg (11 people) | Placebo (9 people) |
|---|---|---|
| ALT, a liver-damage marker | Down 21% | Up 4% |
| AST, a second liver marker | Down 28% | Down 11% |
| Glucose | Down 6% | No change |
| Liver fat (MRI) | Down 5.03 percentage points | Down 4.88 percentage points |
The company reported no serious side effects. In the healthy-volunteer part, people had mild, lasting bumps under the skin where they injected, mostly painless, and after a change of formulation the bumps no longer lasted16. Liver fat fell about as much on placebo, and 20 people for 4 weeks is a small test. Beyond a 2021 liver-meeting presentation, no paper has followed16, and CB4211 is a different molecule from MOTS-c.
What do people who use MOTS-c report?
Commonly reported: a week or two of feeling more tired at the start, then more energy and easier workouts by weeks two to four; mild redness at the injection site; now and then an upset stomach.
These are user reports, not study results. The range people commonly run, 5 to 10 mg two or three times a week, comes from community protocols, not from any controlled study, and it is laid out with that caveat at pepvault.app/lab/dosage/mots-c. The vial math for the usual sizes is at pepvault.app/tools/reconstitution-calculator/mots-c-10mg and pepvault.app/tools/reconstitution-calculator/mots-c-40mg. Because MOTS-c acts on glucose handling in animals, anyone on insulin or other diabetes medicine has a good reason to talk glucose with their doctor.
- Write down your starting point before the first dose: energy, a workout you repeat, and your weight.
- Note side effects with the date, so a tired first week can be told apart from a pattern.
PepVault keeps a two- or three-times-a-week schedule with a reminder for each dose, logs the injection site, and keeps your fasting glucose and HbA1c results in Bloodwork. Set reminders in PepVault
If hives, a swollen face or lips, or trouble breathing follow a dose, get medical care straight away.
How does MOTS-c compare with SS-31 and humanin?
All three are called mitochondrial peptides, but they sit at very different stages. SS-31 (elamipretide) is a lab-designed molecule that binds cardiolipin, a fat in the inner mitochondrial membrane, and the FDA approved it in 2025, as Forzinity, under its accelerated pathway to improve muscle strength in Barth syndrome, a rare inherited disease17. Humanin, like MOTS-c, is written in mitochondrial DNA1, and both run lower in type 2 diabetes9. MOTS-c has strong mouse data and no human trial of its own.
The side-by-sides are at pepvault.app/peptides/compare/mots-c-vs-ss-31 and pepvault.app/peptides/compare/mots-c-vs-humanin, with more at pepvault.app/peptides/compare/nad-vs-mots-c, pepvault.app/peptides/compare/epitalon-vs-mots-c and pepvault.app/peptides/compare/mots-c-vs-slu-pp-332.
Where to read more
- The library page, pepvault.app/peptides/mots-c, with its side effects, how long it takes to work, stacks and legal status pages.
- The study pages, from pepvault.app/research/mots-c-lee-2015 to pepvault.app/research/mots-c-kong-2025 and pepvault.app/research/mots-c-dieli-conwright-2021.
- Terms such as placebo, double-blind and clinical trial phases are in the glossary, pepvault.app/glossary.
- Next guide: SS-31 (elamipretide), what the trials show.
Sources
- Lee C et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015. PubMed 25738459
- UniProt A0A0C5B5G6, Mitochondrial-derived peptide MOTS-c (human, gene MT-RNR1), sequence. rest.uniprot.org
- Reynolds JC et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nat Commun. 2021. PubMed 33473109
- Hyatt JK. MOTS-c increases in skeletal muscle following long-term physical activity and improves acute exercise performance after a single dose. Physiol Rep. 2022. PubMed 35808870
- Kong BS et al. Mitochondrial-encoded peptide MOTS-c prevents pancreatic islet cell senescence to delay diabetes. Exp Mol Med. 2025. PubMed 40855115
- D'Souza RF et al. Increased expression of the mitochondrial derived peptide, MOTS-c, in skeletal muscle of healthy aging men is associated with myofiber composition. Aging (Albany NY). 2020. PubMed 32182209
- Dieli-Conwright CM et al. Effect of aerobic and resistance exercise on the mitochondrial peptide MOTS-c in Hispanic and Non-Hispanic White breast cancer survivors. Sci Rep. 2021. PubMed 34413391
- Elhusseiny R et al. Repeated heat stress modulates the levels of the mitokines MOTS-C and FGF21 in active men during calf muscle immobilization. Med Sci Sports Exerc. 2025. PubMed 40674654
- Ramanjaneya M et al. Mitochondrial-derived peptides are down regulated in diabetes subjects. Front Endocrinol (Lausanne). 2019. PubMed 31214116
- Du C et al. Circulating MOTS-c levels are decreased in obese male children and adolescents and associated with insulin resistance. Pediatr Diabetes. 2018. PubMed 29691953
- Qin Q et al. Downregulation of circulating MOTS-c levels in patients with coronary endothelial dysfunction. Int J Cardiol. 2018. PubMed 29242099
- Zhou Q et al. The correlation between mitochondrial derived peptide (MDP) and metabolic states: a systematic review and meta-analysis. Diabetol Metab Syndr. 2024. PubMed 39160573
- Zempo H et al. A pro-diabetogenic mtDNA polymorphism in the mitochondrial-derived peptide, MOTS-c. Aging (Albany NY). 2021. PubMed 33468709
- U.S. Food and Drug Administration. Certain bulk drug substances for use in compounding that may present significant safety risks (content current as of April 22, 2026). fda.gov
- ClinicalTrials.gov NCT03998514. A phase 1a/1b study of CB4211 in healthy non-obese subjects and subjects with nonalcoholic fatty liver disease. Sponsor: CohBar, Inc. clinicaltrials.gov
- CohBar, Inc. Annual report on Form 10-K for 2021, filed with the U.S. Securities and Exchange Commission, March 29, 2022. sec.gov
- U.S. Food and Drug Administration. Drugs@FDA: NDA 215244, Forzinity (elamipretide), Stealth BioTherapeutics, approved September 19, 2025. accessdata.fda.gov
Newsletter · Weekly
The weekly peptide briefing.
New guides, the week’s peptide news, one tool. Free, one email a week, unsubscribe anytime.